PL3875077T3 - Postać dawkowania zapewniająca przedłużone uwalnianie soli kwasu fosforowego tapentadolu - Google Patents
Postać dawkowania zapewniająca przedłużone uwalnianie soli kwasu fosforowego tapentadoluInfo
- Publication number
- PL3875077T3 PL3875077T3 PL20160419.6T PL20160419T PL3875077T3 PL 3875077 T3 PL3875077 T3 PL 3875077T3 PL 20160419 T PL20160419 T PL 20160419T PL 3875077 T3 PL3875077 T3 PL 3875077T3
- Authority
- PL
- Poland
- Prior art keywords
- tapentadol
- phosphoric acid
- dosage form
- acid salt
- prolonged release
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title 1
- 230000002035 prolonged effect Effects 0.000 title 1
- 229960005126 tapentadol Drugs 0.000 title 1
- -1 tapentadol phosphoric acid salt Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20160419.6A EP3875077B1 (en) | 2020-03-02 | 2020-03-02 | Dosage form providing prolonged release of tapentadol phosphoric acid salt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3875077T3 true PL3875077T3 (pl) | 2024-03-11 |
Family
ID=69743145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20160419.6T PL3875077T3 (pl) | 2020-03-02 | 2020-03-02 | Postać dawkowania zapewniająca przedłużone uwalnianie soli kwasu fosforowego tapentadolu |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP3875077B1 (pl) |
| AU (1) | AU2020202056B2 (pl) |
| ES (1) | ES2968510T3 (pl) |
| HR (1) | HRP20240081T1 (pl) |
| HU (1) | HUE064779T2 (pl) |
| PL (1) | PL3875077T3 (pl) |
| RS (1) | RS65074B1 (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021201351B1 (en) * | 2020-11-10 | 2022-04-21 | Grünenthal GmbH | Dosage form providing prolonged release of a salt of Tapentadol with L-(+)-tartaric acid |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4426245A1 (de) | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
| PE20030527A1 (es) | 2001-10-24 | 2003-07-26 | Gruenenthal Chemie | Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen |
| PL1786403T3 (pl) | 2004-07-01 | 2013-10-31 | Gruenenthal Gmbh | Doustna postać dawki zabezpieczona przed nadużywaniem zawierająca (1R, 2R)-3-(3-dimetyloamino-1-etylo0-2-metylo-propylo)fenol |
| CN101568329A (zh) | 2006-10-27 | 2009-10-28 | 詹森药业有限公司 | 干燥颗粒药用组合物及其生产方法 |
| JP5774853B2 (ja) * | 2008-01-25 | 2015-09-09 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 医薬投薬形 |
| NZ592437A (en) | 2008-10-30 | 2013-03-28 | Gruenenthal Chemie | A dosage form comprising tapentadol and an opioid antagonist |
| KR102146233B1 (ko) | 2010-07-23 | 2020-08-21 | 그뤼넨탈 게엠베하 | ３-(３-디메틸아미노-１-에틸-２-메틸-프로필)-페놀의 염 또는 공결정 |
| WO2012051246A1 (en) | 2010-10-12 | 2012-04-19 | Ratiopharm Gmbh | Tapentadol hydrobromide and crystalline forms thereof |
| US20160136112A1 (en) | 2013-08-02 | 2016-05-19 | Ratiopharm Gmbh | Composition comprising tapentadol in a dissolved form |
| EP2942054A1 (en) | 2014-05-09 | 2015-11-11 | G.L. Pharma GmbH | Slow-release pharmaceutical formulation |
| PL3653599T3 (pl) | 2016-04-19 | 2023-03-20 | Ratiopharm Gmbh | Krystaliczny fosforan tapentadolu |
-
2020
- 2020-03-02 HU HUE20160419A patent/HUE064779T2/hu unknown
- 2020-03-02 EP EP20160419.6A patent/EP3875077B1/en active Active
- 2020-03-02 RS RS20240052A patent/RS65074B1/sr unknown
- 2020-03-02 ES ES20160419T patent/ES2968510T3/es active Active
- 2020-03-02 HR HRP20240081TT patent/HRP20240081T1/hr unknown
- 2020-03-02 PL PL20160419.6T patent/PL3875077T3/pl unknown
- 2020-03-23 AU AU2020202056A patent/AU2020202056B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3875077A1 (en) | 2021-09-08 |
| RS65074B1 (sr) | 2024-02-29 |
| AU2020202056A1 (en) | 2020-05-14 |
| EP3875077C0 (en) | 2023-12-13 |
| ES2968510T3 (es) | 2024-05-10 |
| EP3875077B1 (en) | 2023-12-13 |
| AU2020202056B2 (en) | 2020-10-01 |
| HUE064779T2 (hu) | 2024-04-28 |
| HRP20240081T1 (hr) | 2024-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1257400A1 (zh) | 用於治療疾病的唑來膦酸或相關化合物的經口施用組合物 | |
| IL289496A (en) | Therapeutic uses of oxidizing hypotonic acid solutions | |
| PH12015501015B1 (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
| SG10202012352XA (en) | Triesters of cyclohexanetripropionic acid | |
| IL276689A (en) | Bampedoic acid sustained release formulations | |
| PE20150199A1 (es) | Composiciones farmaceuticas y tratamiento de mastitis | |
| IL264880A (en) | Preparations for oral administration of active substances | |
| IL258117B1 (en) | Hydrophilic gel for local administration of 5-amino levulinic acid | |
| MX364680B (es) | Composicion solida para administracion oral que contiene acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d. | |
| EP4003323A4 (en) | STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES | |
| MX2016001422A (es) | Composicion farmaceutica de fingolimod. | |
| EP3318261A4 (en) | Use of zoledronic acid to prepare drug treating fatty liver disease | |
| RS65074B1 (sr) | Dozni oblik sa produženim oslobađanjem soli tapentadola sa fosfornom kiselinom | |
| IL305851A (en) | Preparation of 2-chloro-4-fluoro-5-nitrobenzoic acid | |
| ZA202103212B (en) | Composition comprising a choline salt of a fatty acid and its use as a fungicide | |
| IL282669B2 (en) | Slow-release formulations of phosphoric acid and phosphite salts | |
| LT3995135T (lt) | Tapentadolio l-(+)-vyno rūgščių druskos pailginto atpalaidavimo | |
| KR101761061B9 (ko) | 키토산페룰산 염 화합물의 제조방법 및 이로부터 제조된 키토산페룰산 염 화합물을 유효성분으로 함유하는 항균성 조성물 | |
| MX2015006356A (es) | Formulacion de capsula de acido 5-aminosalicilico. | |
| ZA201805351B (en) | Improved treatment of implants with phosphonic acid compounds | |
| PT3246032T (pt) | Composições farmacêuticas com ácido zoledrónico, cálcio e vitamina d adequadas para tratamento e/ou profilaxia de doenças do metabolismo ósseo e de efeitos secundários relacionados com terapia, como hipocalcemias | |
| EP3305325A4 (en) | ACTIVE AGENT FOR THE THERAPY OF MENTAL ILLNESSES WITH IL-6 INHIBITOR AS AN ACTIVE AGENT | |
| MX2016017336A (es) | Uso de acido bisfosfonico y sus sales en la preparacion de composiciones utiles en el tratamiento de la osteoporosis. | |
| IN2014CH00984A (pl) | ||
| IN2013MU02366A (pl) |